China: EpimAb Looks to 2022 IPO & Global Leadership in Bispecific…
Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking towards a 2022 IPO with the aim of becoming a globally competitive player…